What is Roxicodone?
Roxicodone contains oxycodone hydrochloride, a full opioid agonist and Schedule II controlled substance, released immediately rather than over many hours. The rules that apply to the molecule — interactions through the liver enzyme CYP3A4, organ impairment and the full boxed warning — are set out on the oxycodone page; this page covers the Roxicodone tablets.1
The FDA approved Roxicodone tablets under NDA 021011 on 31 August 2000; the holder is SpecGx. An extended-release Roxicodone approved in 1998 under a separate application has been discontinued.2
The lower-strength Roxicodone tablet is the reference standard that generic immediate-release oxycodone tablets are tested against, and the Roxicodone tablets carry an AB therapeutic-equivalence rating.52 Roxicodone’s labelling makes no abuse-deterrence claim.1
▶Clinical detailshow the tablets compare
| Dose | Peak level | Time to peak | Half-life |
|---|---|---|---|
| Three 5 mg tablets | 22.3 ng/mL | 1.8 hours | 3.7 hours |
| One 15 mg tablet | 22.2 ng/mL | 1.4 hours | 3.6 hours |
| One 30 mg tablet | 39.3 ng/mL | 2.6 hours | 3.9 hours |
The 15 mg and 30 mg tablets are bioequivalent to the 5 mg tablet, with relative bioavailability of 96% and 101%. Source: 1
